Welcome to our dedicated page for Trinity Biotech Plc news (Ticker: TRIB), a resource for investors and traders seeking the latest updates and insights on Trinity Biotech Plc stock.
Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The TRIB news feed on Stock Titan aggregates company press releases and related coverage so readers can follow developments across its infectious disease, diabetes, oncology and maternal health portfolios.
News items for Trinity Biotech commonly highlight regulatory milestones and product launches. Recent announcements include large orders for its TrinScreen HIV rapid screening test, WHO and in-country regulatory approvals enabling offshored and outsourced manufacturing of TrinScreen HIV and Uni-Gold HIV, and expanded rollout of a high-capacity HbA1c column system for the FDA-cleared Premier Hb9210 analyzer. These updates provide insight into how the company is executing its transformation plan and adjusting its manufacturing footprint.
Investors and observers can also use the TRIB news page to track progress in newer areas such as continuous glucose monitoring, where the company has reported breakthrough clinical trial results for a redesigned CGM sensor and references its CGM+ solution, as well as oncology and maternal health initiatives, including development of the EpiCapture prostate cancer test and the PreClara Ratio preeclampsia biomarker service. Capital structure and governance developments, such as credit agreement amendments with Perceptive Advisors, Nasdaq listing compliance updates, and annual general meeting outcomes, are also disclosed through news and associated SEC filings.
By reviewing the Trinity Biotech news stream, users can see how product approvals, manufacturing changes, financing arrangements and clinical data releases intersect with the company’s stated strategy in diagnostics and diabetes management. This page can be revisited to follow new regulatory clearances, commercial orders, pipeline updates and corporate actions as they are reported by the company.
Trinity Biotech (Nasdaq: TRIB) has received New York State Department of Health (NYSDOH) approval to launch its FDA-cleared PreClara™ Ratio biomarker test for preeclampsia risk assessment in Q3 2025. The test measures sFlt-1/PlGF ratio to evaluate progression risk to severe preeclampsia in hospitalized patients with hypertensive pregnancy disorders.
The test addresses a significant medical need, as approximately 500,000 U.S. women are affected annually by hypertensive pregnancy disorders. Recent studies show potential cost savings exceeding $10 million per 1,000 patients through reduced preterm deliveries and NICU admissions. This approval also supports the future launch of PrePsia™, Trinity's early pregnancy risk assessment technology.
Trinity Biotech (Nasdaq: TRIB) has announced breakthrough clinical trial results for its next-generation continuous glucose monitoring technology, CGM+. The trial demonstrated that their redesigned needle-free glucose sensor can deliver accurate readings over a 15-day wear period without requiring finger-stick calibration.
The company's innovative CGM+ platform features a modular design that reduces disposable components and integrates multiple health metrics including heart activity, body temperature, and physical activity data. This approach aims to significantly lower costs compared to existing market solutions, addressing accessibility barriers in the projected $28 billion CGM market by 2030.
Trinity Biotech (NASDAQ:TRIB) has announced the launch of its FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test for preeclampsia detection through its New York-based reference laboratory in Q3 2025. The test, developed in collaboration with Thermo Fisher Scientific, aims to address hypertensive disorders affecting approximately 500,000 women annually in the United States.
The test enables healthcare providers to make earlier, informed decisions for hospitalized patients by assessing the likelihood of progression to severe preeclampsia. Recent U.S. studies indicate potential neonatal cost savings exceeding $10 million per 1,000 patients when integrated into standard care, primarily through reduced preterm deliveries and NICU admissions.
This launch precedes the planned introduction of PrePsia™, Trinity Biotech's proprietary preeclampsia risk assessment technology for early pregnancy.
Trinity Biotech (Nasdaq: TRIB) has unveiled CGM+, an AI-native continuous glucose monitoring platform targeting the $260 billion AI wearable market. The next-generation wearable biosensor combines glucose monitoring with heart activity, temperature, and physical activity tracking in a single modular device.
The CGM+ platform features a minimally invasive electrochemical glucose sensor and proprietary needle-free technology, designed to reduce disposable components and lower care costs. The company anticipates a commercial launch in mid-2026, targeting both clinical and consumer health markets.
The global CGM market is projected to grow from $13.28B in 2025 to $28.72B by 2030 (16.68% CAGR). Trinity Biotech plans multiple revenue streams, including device sales, AI analytics subscriptions, and strategic partnerships with healthcare providers, insurers, and digital health platforms.
Trinity Biotech (NASDAQ: TRIB), a commercial stage biotechnology company, announced reaching a significant profitability milestone in Q2 2025, projecting to be Adjusted EBITDA-positive going forward. The company expects to achieve meaningful positive Adjusted EBITDA and cash flow from operations starting Q3 2025.
For Q1 2025, Trinity reported revenue of $7.6 million with a gross profit of $1.9 million and an operating loss of $6.5 million. The company projects Q2 2025 revenue to increase significantly to $11-12 million, driven by ramped-up manufacturing under its revised operational structure and normalized demand for rapid HIV tests.
Trinity Biotech continues development of its next-generation continuous glucose monitoring (CGM) solution, targeting the $13 billion global CGM market. The company recently completed a pre-pivotal trial on upgraded sensor technology and plans to unveil key aspects of its innovative design solution soon. Additionally, Trinity is advancing the international rollout of its upgraded diabetes care HbA1c testing product and TrinScreen HIV tests, while progressing on pipeline developments including preeclampsia screening and prostate cancer tests.
Trinity Biotech (NASDAQ:TRIB) has secured World Health Organization (WHO) approval for offshoring and outsourcing the upstream manufacturing of its flagship TrinScreen™ HIV rapid test. This strategic move, set to be implemented in Q3 2025, is a crucial part of the company's transformation plan aimed at improving financial performance and achieving sustainable profitability.
The transition from in-house operations to an outsourced model is expected to deliver significant improvements in gross margins, reduce fixed costs, enhance supply chain resilience, and free up working capital. The company will maintain product integrity and regulatory compliance while focusing internal resources on innovation and market expansion.
Trinity Biotech (TRIB) has received two non-compliance notices from Nasdaq regarding listing requirements. The first notice concerns the company's failure to maintain a minimum bid price of $1.00 per share for its American depositary shares (ADSs). The second notice relates to not meeting the minimum market value of publicly held shares (MVPHS) requirement of $15,000,000.
The company has until September 10, 2025 to regain compliance with both requirements. For the bid price requirement, TRIB must maintain a closing bid price above $1.00 for at least 10 consecutive business days. For the MVPHS requirement, the company must exceed $15,000,000 for a minimum of 10 consecutive business days.
If Trinity fails to meet these requirements, it may be eligible for additional grace periods or could seek transfer to the Nasdaq Capital Market. The notices do not immediately affect TRIB's listing status, and shares continue trading on the Nasdaq Global Select Market.
Trinity Biotech (Nasdaq: TRIB) has appointed Barclays Capital Inc. as its exclusive financial advisor to support its strategic realignment, focusing primarily on Continuous Glucose Monitoring (CGM) technology development. This appointment marks a significant step in the company's transformation plan.
The company's decision follows substantial progress in developing its differentiated CGM technology, which promises to be more affordable, user-focused, and sustainable. CEO John Gillard highlighted strong pre-pivotal clinical trial data and market interest as key factors driving this strategic direction.
The transformation plan aims to achieve near-term profitability improvements while optimizing the company's portfolio to support CGM-related growth. Barclays will actively assess how Trinity Biotech's existing businesses can align with this new strategic focus.
Trinity Biotech (TRIB) has secured an additional $4 million in debt financing from Perceptive Advisors to support two key initiatives: the continued development of its continuous glucose monitoring (CGM) technology and the company's transformation plan.
The funding follows previously announced positive results from Trinity's pre-pivotal CGM trial. The company's transformation plan aims to enhance profitability and cash-flow generation across its portfolio of operating businesses. Trinity has already implemented measures to increase operational efficiencies and continues to optimize its business portfolio and capital structure.